Improvements needed to postmarket clinical follow-up, EU industry told
This article was originally published in RAJ Devices
Medical device manufacturers in the European Union are going to have to improve the quantity and quality of their postmarket clinical follow-up activities, a senior UK medical device regulator has warned. There is an increasing realisation that the necessary clinical data is not going to be obtained in the premarket setting.
You may also be interested in...
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.